Drug Profile
SVN 5367/M 57KLH peptide vaccine - MimiVax
Alternative Names: SurVaxM; Survivin peptide mimic vaccine - MimiVax; Survivin-targeted peptide vaccine - MimiVax; SVN53-67/M57-KLH peptide vaccine - MimiVaxLatest Information Update: 16 Jan 2024
Price :
$50
*
At a glance
- Originator Roswell Park Cancer Institute
- Developer MimiVax; National Cancer Institute (USA); Roswell Park Cancer Institute
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Glioblastoma
- No development reported Autoimmune disorders; Glioma; Multiple myeloma; Neuroendocrine tumours
Most Recent Events
- 15 Jan 2024 Roswell Park Cancer Institute plans a phase II trial for Neuroendocrine tumours (Metastatic disease) in USA (SC) (NCT06202066)
- 12 Oct 2023 SVN 5367/M 57KLH peptide vaccine - MimiVax receives Fast Track designation for Glioblastoma [SC,Injection] (Newly diagnosed) in USA
- 28 May 2023 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)